News
Prescient Therapeutics hails collaboration with MD Anderson Cancer Center for blood cancer therapy
Prescient Therapeutics Ltd (ASX:PTX) CEO and managing director Steven Yatomi-Clarke chats with Andrew Scott from Proactive about the company’s strategic collaboration agreement with the University of Texas MD…
News
3 major milestones in 8 weeks as biotech links with US giant
ASX-listed biotech Prescient Therapeutics is crossing a major inflection point on the back of three milestone announcements made within a span of less than eight…
News
Prescient Therapeutics tops-up cash reserves to progress innovative cancer therapies
Prescient Therapeutics tops-up cash reserves to progress innovative cancer therapies
Article, News
Prescient joins up with renowned US cancer centre in fight against blood cancer
Prescient will join with the US’s largest cancer centre with the goal of creating best-in-class, adaptable CAR-T cell therapies to treat hematological malignancies. Clinical stage…
Article, News
Prescient Therapeutics (ASX:PTX) teams up with prestigious cancer centre in the US
Prescient Therapeutics (ASX: PTX) takes a crucial step in advancing its next-generation cell therapy platform, OmniCAR. The clinical-stage oncology player entered into a strategic agreement with The…
Article, News
Prescient Therapeutics to collaborate with largest cancer centre in the US to develop blood cancer treatment
“We believe that OmniCAR is a transformational platform for cellular immunotherapy, and we look forward to testing the potential of this promising TCR-like binder for…
Article, News
Prescient Therapeutics enters strategic collaboration with largest cancer centre in US
Prescient Therapeutics (ASX: PTX) has entered a strategic collaboration with the largest cancer centre in US to create “best-in-class” adaptable CAR-T cell therapies to treat blood…
Article, News
Prescient Therapeutics (ASX:PTX) partners with MD Anderson Cancer Center
Prescient Therapeutics (PTX) has partnered with the largest cancer centre in the US to create best-in-class, adaptable CAR-T cell therapies to treat certain cancer types.
Article, News
Excitement builds as Prescient achieves key milestones in personalised cancer treatment
Prescient’s work is being considered a game-changer in advancing CAR-T therapies for cancer treatment and its leader believes its recent momentum is just the beginning….
Article, News
Prescient Therapeutics announces share purchase plan to raise $8 million
Prescient Therapeutics Ltd (ASX:PTX) managing director and CEO Steven Yatomi-Clarke speaks with Proactive’s Elisha Newell about the company’s announcement of a share purchase plan (SPP), looking…